Disclaimer: This is a user generated content submitted by a member of the WriteUpCafe Community. The views and writings here reflect that of the author and not of WriteUpCafe. If you have any complaints regarding this post kindly report it to us.

Highprevalence of brain tumor is expected to propel growth of theanaplastic astrocytoma treatment market. For instance, according toThe Central Brain Tumor Registry of the United States (2020 CBTRUSStatistical Report), the incidence rate of primary malignant andnon-malignant brain and other central nervous system tumors in theU.S was 23.79 cases per 100,000 for an overall total count of 415,411incident tumors.

Adoptionof combination therapies is expected to supply lucrative growthopportunities for players in the AnaplasticAstrocytoma Treatment Market.For instance, in January 2021, Adastra Pharmaceuticals announced thatits Phase Ib trial of oral small molecule drug zotiraciclib inconjunction with the existing standard of care, temozolomide,deminstrted good results in treating patients with recurrenthigh-grade gliomas (recurrent anaplastic astrocytoma and recurrentglioblastoma). 

Moreover,increasing quantity of treatment centers for brain tumors is alsoexpected to aid in growth of the market. For instance, in March 2020,MagForce AG, a developer of medical devices that generate magnetichyperthermia to treat cancer, and the Hufeland Klinikum GmbH, aprovider of general medical and surgical hospital services, announcedin conclusion of a joint cooperation agreement and the plannedopening of a NanoTherm treatment center for brain tumors at theMühlhausen site in Thuringia, Germany.

ReadMore@  https://bit.ly/3iNEe2r 

Login

Welcome to WriteUpCafe Community

Join our community to engage with fellow bloggers and increase the visibility of your blog.
Join WriteUpCafe